LEEDS, England--(BUSINESS WIRE)--Tissue Regenix Group (AIM:TRX) (“Tissue Regenix” or “The Group”) the regenerative medical devices company announces the appointment of an orthopedic clinical advisory board for the US as the Group continues to gain momentum within this key orthopedic market.
The clinical advisory board consists of 5 experts across varying orthopedic specialities, with special emphasis in ligament reconstruction, meniscal replacement, and cartilage restoration. Included on this Board are:
